IRLAB Therapeutics AB announced that the independent Data Safety Monitoring Board (DSMB) has completed the last of two pre-determined safety and data integrity reviews of the ongoing Phase IIb study of pirepemat. The DSMB unanimously recommends that the study should continue without any changes. In accordance with the previously communicated plan, IRLAB will complete patient recruitment in the third quarter of 2024.

Reviews by the independent safety committee, DSMB, are part of the study protocol for the Phase IIb study of pirespemat, IRL752C003 - React PD. This is the second and final safety and data integrity review of the study and, as on the first occasion in July 2023, the DSMB unanimously recommends that ReactPD can proceed under the approved study protocol without modifications. A DSMB is an independent committee of experts responsible for reviewing clinical trial data on an ongoing basis during a study to ensure the safety of study participants and the validity and integrity of the data.

The DSMB makes recommendations on the continuation, modification or termination of the clinical trial based on the results of the pre-specified data review.